Was about to say something similar. Most drug therapeutics are a reformulation of another drug.
It would simply not make sense for a FDA / EMA to regard two different GLP-1 drugs with different active levels and treatment purposes as the same drug.
IXC has step-changed the value of its portfolio with this development - a portfolio that the market is still significantly under-valuing. And excitingly, pharma M&A is expected to rebound over the next 12-18 months, so IXC's announcement has somewhat fortuitous timing.
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.463M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 125000 | 8.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.8¢ | 5755 | 1 |
View Market Depth
| Last trade - 16.12pm 17/10/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable